Skip to main content

French Single-Cell Analysis Startup Minos Biosciences Raises €1.5M

NEW YORK — French single-cell analysis technology startup Minos Biosciences said on Thursday that it has raised €1.5 million ($1.8 million) in seed funding.

The financing was led by VC firm Elaia Partners through its investment venture with Université Paris Sciences et Lettres (Université PSL).

Minos was founded in 2020 as a spinoff from the Ecole Supérieure de Physique et Chimie Industrielles de Paris (ESPCI Paris – PSL) to develop a high-throughput single-cell analysis platform based on microfluidics, molecular biology, image analysis, and bioinformatic technologies. It has been housed at PC'up Boost, the ESPCI Paris – PSL incubator at the Institut Pierre-Gilles de Gennes.

"The seed round … will allow Minos to considerably accelerate its development by reinforcing its R&D team, developing its first prototype, and validating its first applications in close collaboration with top academic laboratories and institutions," Minos Chief Operating Officer Pierre Le Ber said in a statement. "It will also allow Minos to prepare the industrial prototyping phase of its solution."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.